CIK: 0002039349
Total reported value
$143.6M
Reporting period: 2026-03-31 · Number of holdings: 16
GordonMD Global Investments LP disclosed 16 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $143.6M and a quarterly turnover rate of 54.2%.
Browse other institutions with $100M to $1B AUMBrowse other institutions starting with "G"
GordonMD Global Investments LP's disclosed holdings carry a Herfindahl concentration index of 0.118 — mathematically equivalent to about 8 equally-sized positions, well below its 16 actual disclosed holdings. That gap points to a strategy built around a small core of high-conviction bets rather than broad diversification.
Position sizes are fairly uniform across the portfolio (a coefficient of variation of 0.98), suggesting a disciplined, rules-based approach to how much capital goes into each idea.
Recent activity leans toward adding more aggressively to already-large existing positions than to newly initiated ones (a 7.0 percentage-point tilt) — a pattern consistent with a momentum-following approach.
Sector classification currently covers about 5% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Trim TEVA
+63.4% -$18.4M
Add TSHA
-44.6% $14.9M
Add VIR
+63.2% $8.0M
Trim CRNX
-43.3% -$5.8M
Trim KYTX
-3.3% -$4.7M
Trim TARS
-36.0% -$2.5M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | KYTX | Kyverna Therapeutics INC | Stock-Other | 25.51% | -4.09% | -3.35% | |
| 2 | TSHA | Taysha Gene Therapies INC | Stock-Other | 15.47% | +10.22% | -44.58% | |
| 3 | VIR | Vir Biotechnology INC | Stock-Other | 9.48% | +5.46% | +63.23% | |
| 4 | BLCO | Bausch + Lomb CORP | Stock-Other | 6.35% | -1.16% | -6.52% | |
| 5 | AMGN | Amgen INC | Stock-Healthcare | 4.95% | -0.50% | -12.92% | |
| 6 | SRRK | Scholar Rock Holding CORP | Stock-Other | 4.54% | +4.54% | NEW | |
| 7 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 4.22% | -1.21% | -12.15% | |
| 8 | PYXS | Pyxis Oncology INC | Stock-Other | 4.19% | +0.79% | — | |
| 9 | TEVA | Teva Pharmaceutical-sp Adr | Stock-Healthcare | 3.91% | -13.31% | +63.41% | |
| 10 | SION | Sionna Therapeutics INC | Stock-Other | 3.80% | +3.80% | NEW | |
| 11 | CLDX | Celldex Therapeutics INC | Stock-Other | 3.76% | +0.44% | — | |
| 12 | INSM | Insmed INC | Stock-Healthcare | 3.26% | -0.31% | — | |
| 13 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 3.21% | -4.27% | -43.34% | |
| 14 | INCY | Incyte CORP | Stock-Healthcare | 2.84% | -1.02% | -20.55% | |
| 15 | ALLO | Allogene Therapeutics INC | Stock-Other | 2.43% | +2.43% | NEW | |
| 16 | TARS | Tarsus Pharmaceuticals INC | Stock-Other | 2.09% | -1.82% | -35.99% |
Performance for Q3 2026
+3.5%
Performance Last 4 Quarters
+4.5%
Based on 5 months of available history
Based on 76% of reported portfolio value with available pricing
GordonMD Global Investments LP's most significant position changes for 2026-03-31: New buy: Scholar Rock Holding CORP (SRRK); New buy: Sionna Therapeutics INC (SION); New buy: Allogene Therapeutics INC (ALLO); Add: Teva Pharmaceutical-sp Adr (TEVA) — shares +63.41%; Trim: Taysha Gene Therapies INC (TSHA) — shares -44.58%.
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | TSHA | Taysha Gene Therapies INC | +10.2% | -44.58% | Trim |
| 2 | VIR | Vir Biotechnology INC | +5.5% | +63.23% | Add |
| 3 | PYXS | Pyxis Oncology INC | +0.8% | — | Unchanged |
| 4 | CLDX | Celldex Therapeutics INC | +0.4% | — | Unchanged |
| 5 | INSM | Insmed INC | -0.3% | — | Unchanged |
| 6 | AMGN | Amgen INC | -0.5% | -12.92% | Trim |
| 7 | INCY | Incyte CORP | -1% | -20.55% | Trim |
| 8 | BLCO | Bausch + Lomb CORP | -1.2% | -6.52% | Trim |
| 9 | RARE | Ultragenyx Pharmaceutical In | -1.2% | -12.15% | Trim |
| 10 | TARS | Tarsus Pharmaceuticals INC | -1.8% | -35.99% | Trim |
| 11 | KYTX | Kyverna Therapeutics INC | -4.1% | -3.35% | Trim |
| 12 | CRNX | Crinetics Pharmaceuticals In | -4.3% | -43.34% | Trim |
| 13 | TEVA | Teva Pharmaceutical-sp Adr | -13.3% | +63.41% | Add |
| 14 | SRRK | Scholar Rock Holding CORP | — | NEW | New buy |
| 15 | SION | Sionna Therapeutics INC | — | NEW | New buy |
| 16 | ALLO | Allogene Therapeutics INC | — | NEW | New buy |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-05-15 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-02-17 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0002109652
Total reported value
$143.6M
50 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001725722
Total reported value
$143.5M
4 stks
2022-09-30
Stale — no recent filing
AUM within 0.1% of this institution
CIK 0002093444
Total reported value
$143.7M
60 stks
2026-03-31
AUM within 0.1% of this institution
Institutions with overlapping top holdings
CIK 0000019481
Total reported value
$362.5M
450 stks
2026-03-31
1 of the top 5 holdings overlap, including Amgen INC
CIK 0000882095
Total reported value
$2.1B
6 stks
2026-03-31
1 of the top 5 holdings overlap, including Kyverna Therapeutics INC
CIK 0000942257
Total reported value
$296.8M
65 stks
2023-09-30
Stale — no recent filing
1 of the top 5 holdings overlap, including Amgen INC